Publications by authors named "Gary Pratt"

Claim this Profile
B
Biopsy decision for intermediate-high-risk lung nodules is significantly changed when guided by prior positron emission tomography/CT (PET/CT) results: results of the prospective PET-FIRST study.
David Fielding, Calvin Sidhu, Mahmoud Alkhater, Moayed Alawami, Stephan E P Kops, Gary Pratt

BMJ Open Respir Res· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Trial of Inducible Caspase 9 T Cells in Adult Stem Cell Transplant Demonstrates Massive Clonotypic Proliferative Potential and Long-term Persistence of Transgenic T Cells.
Ping Zhang, Jyothy Raju, Md Ashik Ullah, Raymond Au, Antiopi Varelias, Gary R Pratt

Clin Cancer Res· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Concurrent chemoradiation with cisplatin and vinorelbine followed by consolidation with oral vinorelbine in locally advanced non-small cell lung cancer (NSCLC): the phase II CONCAVE study.
Brett Gm Hughes, Elizabeth Ahern, Margot Lehman, Gary Pratt, Margaret Dauth

Asia Pac J Clin Oncol· June 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Recent advances in radiotherapy for thoracic tumours.
Michael Fay, Christopher M Poole, Gary Pratt

J Thorac Dis· October 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A retrospective analysis of survival outcomes for two different radiotherapy fractionation schedules given in the same overall time for limited stage small cell lung cancer.
Catherine S Bettington, Lee Tripcony, Guy Bryant, Brigid Hickey, Gary Pratt

J Med Imaging Radiat Oncol· February 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited chemotherapy and shrinking field radiotherapy for Osteolymphoma (primary bone lymphoma): results from the trans-Tasman Radiation Oncology Group 99.04 and Australasian Leukaemia and Lymphoma Group LY02 prospective trial.
David Christie, Keith Dear, Thai Le, Michael Barton, Andrew Wirth, Gary Pratt

Int J Radiat Oncol Biol Phys· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human immunodeficiency virus (HIV) in older people.
Gary Pratt, Kate Gascoyne, Katherine Cunningham, Anne Tunbridge

Age Ageing· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Designation does matter.
Gary M Pratt

Arch Surg· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Demographics and outcomes at American Society for Metabolic and Bariatric Surgery Centers of Excellence.
Gary M Pratt, Chris A Learn, Gail D Hughes, Bobby L Clark, Mike Warthen

Surg Endosc· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of individual fraction size data from 3756 patients to directly determine the alpha/beta ratio of prostate cancer.
Scott G Williams, Jeremy M G Taylor, Ning Liu, Yolande Tra, Gillian M Duchesne, Gary R Pratt

Int J Radiat Oncol Biol Phys· May 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The ASBS Bariatric Surgery Centers of Excellence program: a blueprint for quality improvement.
Gary M Pratt, Byron McLees, Walter J Pories

Surg Obes Relat Dis· January 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A multicenter study demonstrating discordant results from electronic prostate-specific antigen biochemical failure calculation systems.
Scott G Williams, Tom Pickles, Larry Kestin, Louis Potters, Paul Fearn, Gary Pratt

Int J Radiat Oncol Biol Phys· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An international multicenter study evaluating the impact of an alternative biochemical failure definition on the judgment of prostate cancer risk.
Scott G Williams, Gillian M Duchesne, N Kumar Gogna, Jeremy L Millar, Tom Pickles, Gary R Pratt

Int J Radiat Oncol Biol Phys· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Combined-modality therapy for primary central nervous system lymphoma: long-term data from a Phase II multicenter study (Trans-Tasman Radiation Oncology Group).
Peter C O'Brien, Daniel E Roos, Gary Pratt, K-H Liew, Michael B Barton

Int J Radiat Oncol Biol Phys· February 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Long-term outcome after radiotherapy alone for lymphocyte-predominant Hodgkin lymphoma: a retrospective multicenter study of the Australasian Radiation Oncology Lymphoma Group.
Andrew Wirth, Kally Yuen, Michael Barton, Daniel Roos, Kumar Gogna, Gary Pratt

Cancer· September 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Both pretreatment prostate-specific antigen level and posttreatment biochemical failure are independent predictors of overall survival after radiotherapy for prostate cancer.
Scott G Williams, Gillian M Duchesne, Jeremy L Millar, Gary R Pratt

Int J Radiat Oncol Biol Phys· November 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis